# Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

> **NCT04225676** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel

## Key facts

- **NCT ID:** NCT04225676
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-19
- **Primary completion:** 2021-10-19
- **Final completion:** 2021-10-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Terminated due to slow enrollment
- **Last updated:** 2023-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225676, "Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04225676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*